Hepatitis D – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Hepatitis D – Pipeline Review, H1 2020’, provides an overview of the Hepatitis D pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hepatitis D

– The report reviews pipeline therapeutics for Hepatitis D by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hepatitis D therapeutics and enlists all their major and minor projects

– The report assesses Hepatitis D therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hepatitis D

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hepatitis D

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatitis D pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

CN Bio Innovations Ltd

Eiger BioPharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Globeimmune Inc

Hepion Pharmaceuticals Inc

Merck & Co Inc

MYR GmbH

PharmaEssentia Corp

Replicor Inc

Rodos BioTarget GmbH

SomaGenics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatitis D - Overview

Hepatitis D - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis D - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis D - Companies Involved in Therapeutics Development

CN Bio Innovations Ltd

Eiger BioPharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Globeimmune Inc

Hepion Pharmaceuticals Inc

Merck & Co Inc

MYR GmbH

PharmaEssentia Corp

Replicor Inc

Rodos BioTarget GmbH

SomaGenics Inc

Hepatitis D - Drug Profiles

Antisense RNAi Oligonucleotide for Hepatitis D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bulevirtide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRV-431 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-18000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lonafarnib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon alfa-2a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon lambda-1a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBT-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2165 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ropeginterferon alfa-2b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Hepatitis D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Hepatitis B and Hepatitis D Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vanitaracin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis D - Dormant Projects

Hepatitis D - Product Development Milestones

Featured News & Press Releases

Nov 12, 2019: Eiger announces Peginterferon Lambda - Lonafarnib combination interim results in Hepatitis Delta Virus (HDV) infection from phase 2 LIFT study during late-breaker oral presentation at AASLD 2019

Nov 01, 2019: MYR Pharmaceuticals announces multiple presentations at the AASLD Meeting 2019 in Boston

Oct 21, 2019: Eiger announces Peginterferon Lambda combination therapy for treatment of chronic hepatitis delta virus (HDV) infection to be featured in a late-breaking oral presentation at AASLD 2019

Aug 20, 2019: Eiger announces FDA breakthrough therapy designation for Peginterferon Lambda for treatment of hepatitis delta virus infection

Jul 29, 2019: Replicor announces publication of new study examining HBsAg evolution during REP 2139

Jun 10, 2019: Replicor presents final REP 401 data demonstrating persistent functional cure of HBV

May 17, 2019: Eiger BioPharmaceuticals announces transition of Chief Operating Officer and Executive Medical Officer

Apr 11, 2019: Eiger Announces 36% durable virologic response at 24 weeks post-treatment with peginterferon lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019

Apr 04, 2019: MYR Pharmaceuticals announces presentation of final results of the MYR203 study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna

Apr 01, 2019: Replicor to present latest data on the beneficial impact of transaminase flares in achieving HBV functional cure at the 2019 EASL ILC meeting

Mar 26, 2019: Eiger BioPharmaceuticals to Participate in Conferences in April 2019

Mar 26, 2019: Eiger BioPharmaceuticals to participate in conferences

Mar 13, 2019: Eiger late-breaker oral presentation of peginterferon lambda Phase 2 LIMT study at The International Liver Congress 2019

Mar 05, 2019: MYR Pharma announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the first-in-class entry inhibitor for treatment of chronic hepatitis d infections

Feb 06, 2019: Eiger Biopharmaceuticals announces patent protection for Lonafarnib boosted with Ritonavir for treatment of hepatitis delta virus infection in Europe and Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hepatitis D, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Hepatitis D – Pipeline by CN Bio Innovations Ltd, H1 2020

Hepatitis D – Pipeline by Eiger BioPharmaceuticals Inc, H1 2020

Hepatitis D – Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Hepatitis D – Pipeline by Globeimmune Inc, H1 2020

Hepatitis D – Pipeline by Hepion Pharmaceuticals Inc, H1 2020

Hepatitis D – Pipeline by Merck & Co Inc, H1 2020

Hepatitis D – Pipeline by MYR GmbH, H1 2020

Hepatitis D – Pipeline by PharmaEssentia Corp, H1 2020

Hepatitis D – Pipeline by Replicor Inc, H1 2020

Hepatitis D – Pipeline by Rodos BioTarget GmbH, H1 2020

Hepatitis D – Pipeline by SomaGenics Inc, H1 2020

Hepatitis D – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Hepatitis D, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports